JPWO2022204730A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022204730A5 JPWO2022204730A5 JP2023558179A JP2023558179A JPWO2022204730A5 JP WO2022204730 A5 JPWO2022204730 A5 JP WO2022204730A5 JP 2023558179 A JP2023558179 A JP 2023558179A JP 2023558179 A JP2023558179 A JP 2023558179A JP WO2022204730 A5 JPWO2022204730 A5 JP WO2022204730A5
- Authority
- JP
- Japan
- Prior art keywords
- immune cell
- cancer
- cell type
- dna
- methylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims description 136
- 238000000034 method Methods 0.000 claims description 131
- 230000011987 methylation Effects 0.000 claims description 84
- 238000007069 methylation reaction Methods 0.000 claims description 84
- 108020004414 DNA Proteins 0.000 claims description 83
- 206010028980 Neoplasm Diseases 0.000 claims description 83
- 201000011510 cancer Diseases 0.000 claims description 80
- 239000000523 sample Substances 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 39
- 230000001973 epigenetic effect Effects 0.000 claims description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 238000012163 sequencing technique Methods 0.000 claims description 21
- 210000004698 lymphocyte Anatomy 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 210000000440 neutrophil Anatomy 0.000 claims description 14
- 238000000638 solvent extraction Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000012636 effector Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 230000030933 DNA methylation on cytosine Effects 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 210000003979 eosinophil Anatomy 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 210000003887 myelocyte Anatomy 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 7
- 208000003200 Adenoma Diseases 0.000 claims description 6
- 206010001233 Adenoma benign Diseases 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 230000007306 turnover Effects 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 108091005646 acetylated proteins Proteins 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 108091005592 methylated proteins Proteins 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010024291 Leukaemias acute myeloid Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 201000007698 cell type cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 210000003026 hypopharynx Anatomy 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000013507 mapping Methods 0.000 claims description 2
- 210000001237 metamyelocyte Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000001989 nasopharynx Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000003695 paranasal sinus Anatomy 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102000014961 Protein Precursors Human genes 0.000 claims 1
- 108010078762 Protein Precursors Proteins 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000004565 granule cell Anatomy 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166200P | 2021-03-25 | 2021-03-25 | |
| US63/166,200 | 2021-03-25 | ||
| PCT/US2022/071365 WO2022204730A1 (en) | 2021-03-25 | 2022-03-25 | Methods and compositions for quantifying immune cell dna |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511425A JP2024511425A (ja) | 2024-03-13 |
| JPWO2022204730A5 true JPWO2022204730A5 (https=) | 2025-04-01 |
| JP2024511425A5 JP2024511425A5 (https=) | 2025-04-01 |
Family
ID=81346077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558179A Pending JP2024511425A (ja) | 2021-03-25 | 2022-03-25 | 免疫細胞ｄｎａを定量するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240344115A1 (https=) |
| EP (1) | EP4314329A1 (https=) |
| JP (1) | JP2024511425A (https=) |
| WO (1) | WO2022204730A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025038399A1 (en) * | 2023-08-11 | 2025-02-20 | Guardant Health, Inc. | Methylated enrichment methods for single-molecule genetic and epigenetic sequencing |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20030017081A1 (en) | 1994-02-10 | 2003-01-23 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| AU2002359522A1 (en) | 2001-11-28 | 2003-06-10 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
| CA2519860C (en) | 2003-03-21 | 2018-01-16 | Santaris Pharma A/S | Short interfering rna (sirna) analogues |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| US9116118B2 (en) | 2012-06-08 | 2015-08-25 | Pacific Biosciences Of California, Inc. | Modified base detection with nanopore sequencing |
| GB2533006B (en) | 2012-09-04 | 2017-06-07 | Guardant Health Inc | Systems and methods to detect copy number variation |
| CN107002122B (zh) | 2014-07-25 | 2023-09-19 | 华盛顿大学 | 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法 |
| US11384382B2 (en) * | 2016-04-14 | 2022-07-12 | Guardant Health, Inc. | Methods of attaching adapters to sample nucleic acids |
| JP2019521673A (ja) * | 2016-06-07 | 2019-08-08 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | 疾患および状態の分析のためのセルフリーｄｎａメチル化パターン |
| KR102610098B1 (ko) | 2016-07-06 | 2023-12-04 | 가던트 헬쓰, 인크. | 무세포 핵산의 프래그멘톰 프로파일링을 위한 방법 |
| US9850523B1 (en) | 2016-09-30 | 2017-12-26 | Guardant Health, Inc. | Methods for multi-resolution analysis of cell-free nucleic acids |
| CA3046007A1 (en) | 2016-12-22 | 2018-06-28 | Guardant Health, Inc. | Methods and systems for analyzing nucleic acid molecules |
| EP4567131A3 (en) * | 2019-01-31 | 2025-09-03 | Guardant Health, Inc. | Compositions and methods for isolating cell-free dna |
| US20220154285A1 (en) * | 2020-09-30 | 2022-05-19 | Guardant Health, Inc. | Analysis of methylated dna comprising methylation-sensitive or methylation-dependent restrictions |
| WO2024073508A2 (en) * | 2022-09-27 | 2024-04-04 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
-
2022
- 2022-03-25 EP EP22718032.0A patent/EP4314329A1/en active Pending
- 2022-03-25 JP JP2023558179A patent/JP2024511425A/ja active Pending
- 2022-03-25 WO PCT/US2022/071365 patent/WO2022204730A1/en not_active Ceased
-
2023
- 2023-09-19 US US18/470,187 patent/US20240344115A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139162A (ja) | メチローム解析を用いる癌の検出及び分類 | |
| US10829821B2 (en) | Leukemia methylation markers and uses thereof | |
| NZ788335A (en) | Determination of base modifications of nucleic acids | |
| CN111755072B (zh) | 一种同时检测甲基化水平、基因组变异和插入片段的方法及装置 | |
| JP2020504606A (ja) | 核酸分子を解析するための方法およびシステム | |
| Jang et al. | Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma | |
| WO2022226231A1 (en) | Liver cancer methylation and protein markers and their uses | |
| CN119923475A (zh) | 用于检测和减少样品制备诱导的甲基化人为假象的方法 | |
| JPWO2021067484A5 (https=) | ||
| KR20240046525A (ko) | 세포-유리 dna에 대한 tet-보조 피리딘 보란 시퀀싱과 관련된 조성물 및 방법 | |
| JPWO2022204730A5 (https=) | ||
| McCafferty et al. | A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements | |
| JPWO2022115810A5 (https=) | ||
| EP4372103A1 (en) | Substance and method for tumor assessment | |
| US20220127601A1 (en) | Method of determining the origin of nucleic acids in a mixed sample | |
| CN116529394A (zh) | 使用分区和甲基化依赖性核酸酶分析dna的组合物和方法 | |
| CN119242823B (zh) | 基于基因甲基化检测实现人t淋巴细胞计数的试剂盒 | |
| US20250218587A1 (en) | Methods and systems for identifying tumor origin | |
| US20250201344A1 (en) | Methods and systems for identifying an origin of a variant | |
| CN119372341B (zh) | 基于基因甲基化检测实现人nk淋巴细胞计数的试剂盒 | |
| Richman | Epigenetic Mechanisms of Ikaros Mediated Tumor Suppression in B-Cell Acute Lymphoblastic Leukemia | |
| JPWO2022087309A5 (https=) | ||
| WO2026050179A1 (en) | Tumor fraction (tf) is associated with real-world progression-free survival (rwpfs) in non-small-cell lung cancer (nsclc) patients treated with platinum-based chemotherapy (chemo) | |
| WO2026024956A1 (en) | Selecting low technical noise biomarkers for sensitive molecular diagnostics | |
| US20220145368A1 (en) | Methods for noninvasive prenatal testing of fetal abnormalities |